<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04642963</url>
  </required_header>
  <id_info>
    <org_study_id>SMART-VT</org_study_id>
    <nct_id>NCT04642963</nct_id>
  </id_info>
  <brief_title>Stereotactic Management of Arrhythmia - Radiosurgery in Treatment of Ventricular Tachycardia</brief_title>
  <acronym>SMART-VT</acronym>
  <official_title>Stereotactic Management of Arrhythmia - Radiosurgery in Treatment of Ventricular Tachycardia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maria Sklodowska-Curie Institute - Oncology Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maria Sklodowska-Curie Institute - Oncology Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective single-arm study investigating the safety of non-invasive cardiac radiosurgery&#xD;
      for the treatment of ventricular tachycardia (VT).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The standard of care for the treatment of Ventricular Tachycardia (VT) comprises of&#xD;
      pharmacotherapy, ICD implantation and electrophysiology-guided catheter ablation. The&#xD;
      treatment, however, is associated with a relatively high risk of VT recurrence. Given the&#xD;
      limited therapeutic options and significant impact on patients quality of life, non-invasive&#xD;
      cardiac radiosurgery has been recently gaining popularity in scientific literature as a&#xD;
      viable alternative to salvage catheter ablations. Considering the scarcity of data from&#xD;
      prospective trials and concern about the safety of the treatment method, this trial seeks to&#xD;
      determine whether Stereotactic Management of Arrhythmia - Radiosurgery in Treatment of&#xD;
      Ventricular Tachycardia (SMART-VT) meets the expected safety requirements for clinical use.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 11, 2020</start_date>
  <completion_date type="Anticipated">January 11, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 11, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute toxicity evaluated using CTCAE v5.0 scale</measure>
    <time_frame>3 months</time_frame>
    <description>The study aims to demonstrate the safety of the treatment method defined as 3-month observation without Grade III or higher adverse events in at least 6 out of 7 patients (1st stage), and in total in at least 9 out of 11 patients (2nd stage) with an interim safety analysis after obtaining data on primary outcome in first 7 patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of the treatment</measure>
    <time_frame>24 months</time_frame>
    <description>Reduction of VT burden, ICD shocks and improvement in life quality as described by SF-36 v2 questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical markers of cardiac injury</measure>
    <time_frame>24 months</time_frame>
    <description>Intensity and dynamics of changes in cardiac-related biochemical indices after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late toxicity and mortality</measure>
    <time_frame>24 months</time_frame>
    <description>Assessment of late toxicity including occurrence of cardiac-related hospitalizations and death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-arrhythmic drugs uptake</measure>
    <time_frame>24 months</time_frame>
    <description>Changes in the anti-arrhythmic medications over time after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac injury</measure>
    <time_frame>24 months</time_frame>
    <description>Assessment of the post-treatment cardiac injury including left ventricular ejection fraction, echocardiography and morphological changes in MRI/PET.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target volume delineation</measure>
    <time_frame>24 months</time_frame>
    <description>Correlation of electrophysiological mapping with the results of additional cardiac imaging methods (MR, PET) - only in applicable patients (optional diagnostic methods)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">11</enrollment>
  <condition>Ventricular Tachycardia</condition>
  <arm_group>
    <arm_group_label>Cardiac Radiosurgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with ventricular tachycardia will undergo a non-invasive cardiac radiosurgery using one fraction of 25 Gy to the arrhythmia substrate, as determined by the electrophysiological cardiac mapping.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Cardiac Radiosurgery</intervention_name>
    <description>Non-invasive delivery of ablative radiotherapy dose to the arrhythmia substrate.</description>
    <arm_group_label>Cardiac Radiosurgery</arm_group_label>
    <other_name>Stereotactic Arrhythmia Radioablation (STAR)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with structural heart disease and implantable cardioverter defibrillator&#xD;
             (ICD)&#xD;
&#xD;
          -  Clinically significant arrhythmia with at least 3 VT episodes per month despite&#xD;
             adequate pharmacological treatment.&#xD;
&#xD;
          -  At least one episode of monomorphic VT registered in electrophysiological examination.&#xD;
&#xD;
          -  Recurrent VT despite at least one prior catheter ablation and adequate pharmacotherapy&#xD;
             OR contraindications to catheter ablation and/or pharmacotherapy (i.e., patient with&#xD;
             medically contraindicated catheter ablation is obliged to undergo only pharmacotherapy&#xD;
             prior to study enrollment).&#xD;
&#xD;
          -  Patient must be able to understand and be willing to sign a written informed consent&#xD;
             document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Heart failure requiring inotropic treatment or mechanical assistance&#xD;
&#xD;
          -  Arrhythmia due to cardiac channelopathy&#xD;
&#xD;
          -  Reversible source of arrhythmia&#xD;
&#xD;
          -  NYHA (New York Heart Association) stage IV hearth failure&#xD;
&#xD;
          -  Hearth infarction or cardiac surgery in last 3 months&#xD;
&#xD;
          -  Life expectancy &lt;6 months&#xD;
&#xD;
          -  Polymorphic VT&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Prior radiotherapy to the thoracic region (relative contraindication)&#xD;
&#xD;
          -  Failure to induce VT during electrophysiological examination&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sławomir Blamek, dr hab. n. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maria Sklodowska-Curie National Research Institute of Oncology (MSCNRIO)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wojciech Wojakowski, prof. dr hab. n. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Upper Silesian Medical Center Professor Leszek Giec of the Medical University of Silesia in Katowice</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marcin Miszczyk, dr n. med.</last_name>
    <role>Study Chair</role>
    <affiliation>Maria Sklodowska-Curie National Research Institute of Oncology (MSCNRIO)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sławomir Blamek, dr hab. n. med.</last_name>
    <phone>784 067 547</phone>
    <phone_ext>+48</phone_ext>
    <email>slawomir.blamek@io.gliwice.pl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marcin Miszczyk, dr n. med.</last_name>
    <phone>663 040 809</phone>
    <phone_ext>+48</phone_ext>
    <email>marcin.miszczyk@io.gliwice.pl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Upper Silesian Medical Center Professor Leszek Giec of the Medical University of Silesia in Katowice</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tomasz Jadczyk, dr n. med.</last_name>
      <phone>512099211</phone>
      <phone_ext>+48</phone_ext>
      <email>tomasz.jadczyk@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maria Sklodowska-Curie National Research Institute of Oncology (MSCNRIO), Gliwice branch</name>
      <address>
        <city>Gliwice</city>
        <state>Śląskie</state>
        <zip>44-102</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcin Miszczyk, dr n. med.</last_name>
      <phone>663 040 809</phone>
      <phone_ext>+48</phone_ext>
      <email>marcin.miszczyk@io.gliwice.pl</email>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 19, 2020</study_first_submitted>
  <study_first_submitted_qc>November 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2020</study_first_posted>
  <last_update_submitted>November 19, 2020</last_update_submitted>
  <last_update_submitted_qc>November 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Maria Sklodowska-Curie Institute - Oncology Center</investigator_affiliation>
    <investigator_full_name>Slawomir Blamek</investigator_full_name>
    <investigator_title>dr hab. n. med.</investigator_title>
  </responsible_party>
  <keyword>Ventricular Tachycardia</keyword>
  <keyword>Ablation</keyword>
  <keyword>Noninvasive</keyword>
  <keyword>Stereotactic Body Radiation Therapy</keyword>
  <keyword>Radiosurgery</keyword>
  <keyword>Substrate Ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>The data will be shared within the European STOPSTORM consortium, which is dedicated to the development of cardiac radiosurgery for the treatment of ventricular tachycardia. The intention to share anonymized data with the consortium will be clearly explained, and a written consent will be obtained from each participant.</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

